Stockreport

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune, Inc.  (EVMN) 
PDF - Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU)- Well capital [Read more]